Recovery in patients with major depressive disorder (MDD): results of a 6-month, multinational, observational study

被引:23
作者
Novick, Diego [1 ]
Montgomery, William [2 ]
Vorstenbosch, Ellen [3 ]
Victoria Moneta, Maria [3 ]
Duenas, Hector [4 ]
Maria Haro, Josep [3 ]
机构
[1] Eli Lilly & Co, Windlesham, Surrey, England
[2] Eli Lilly Australia Pty Ltd, West Ryde, NSW, Australia
[3] Univ Barcelona, CIBERSAM, Fdn St Joan de Deu, Parc Sanitari St Joan de Deu, Barcelona, Spain
[4] Eli Lilly Mexico, Mexico City, DF, Mexico
关键词
remission; functional impairment; clinical remission; course of illness; disability; predictors; SEROTONIN REUPTAKE INHIBITORS; EMERGENT SEXUAL DYSFUNCTION; REMISSION RATES; SELF-REPORT; ADHERENCE; SEVERITY; VENLAFAXINE; PREDICTORS; OUTCOMES; ILLNESS;
D O I
10.2147/PPA.S138750
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Not all individuals treated for major depressive disorder (MDD) achieve recovery. This observational study examined the recovery rates in MDD patients and the patient characteristics associated with achieving recovery in a naturalistic clinical setting. Recovery was defined as having both clinical and functional remission. Data for this post hoc analysis were taken from a 24-week prospective, observational study that involved 1,549 MDD patients. Clinical remission was assessed using the 16-item Quick Inventory of Depressive Symptomatology Self-Report and functional remission through the Sheehan Disability Scale and no days of reduced productivity in the previous week. Generalized estimating equation regression models were used to examine the baseline factors associated with recovery during follow-up. Clinical and functional remission was achieved in 70.6% and 56.1% of the MDD patients, respectively. MDD patients who achieved recovery (52.1%) were significantly less likely to have impaired levels of functioning, concurrent medical or psychiatric conditions, low levels of education, or nonadherence to therapy at follow-up. The level of functioning during the index episode seems to be a better predictor of recovery than symptom severity. Therefore, the level of functioning should be considered while determining recovery from depression.
引用
收藏
页码:1859 / 1868
页数:10
相关论文
共 64 条
[1]  
Åkerblad AC, 2006, INT CLIN PSYCHOPHARM, V21, P117
[2]   Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners [J].
Åkerblad, AC ;
Bengtsson, F ;
Ekselius, L ;
von Knorring, L .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2003, 18 (06) :347-354
[3]  
American Psychiatric Association, 2000, Text Revision (DSM-IV-TR), V4th, DOI DOI 10.1176/APPI.BOOKS.9780890423349
[5]  
[Anonymous], 2000, Am J Psychiatry, V157, P1
[6]   World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects [J].
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20) :2191-2194
[7]  
Anthony W.A., 1993, Psychosocial Rehabilitation Journal, V16, P11, DOI DOI 10.1037/H0095655
[8]   Recovery as the New Medical Model for Psychiatry [J].
Barber, Mary E. .
PSYCHIATRIC SERVICES, 2012, 63 (03) :277-279
[9]   The validity of the CGI severity and improvement scales as measures of clinical effectiveness suitable for routine clinical use [J].
Berk, Michael ;
Ng, Felicity ;
Dodd, Seetal ;
Callaly, Tom ;
Campbell, Shirley ;
Bernardo, Michelle ;
Trauer, Tom .
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, 2008, 14 (06) :979-983
[10]   PERFORMANCE OF A 5-ITEM MENTAL-HEALTH SCREENING-TEST [J].
BERWICK, DM ;
MURPHY, JM ;
GOLDMAN, PA ;
WARE, JE ;
BARSKY, AJ ;
WEINSTEIN, MC .
MEDICAL CARE, 1991, 29 (02) :169-176